MRK ▲ +0.6% - Merck & Co., Inc. $MRK - Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season 13-NOV-2026 06:47 AM ET